Loading clinical trials...
Loading clinical trials...
PHASE 1B/PHASE 3 MULTICENTER STUDY OF AVELUMAB (MSB0010718C) IN COMBINATION REGIMENS THAT INCLUDE AN IMMUNE AGONIST, EPIGENETIC MODULATOR, CD20 ANTAGONIST AND/OR CONVENTIONAL CHEMOTHERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) JAVELIN DLBCL
Conditions
Interventions
Avelumab
Utomilumab
+5 more
Locations
29
United States
City of Hope
Duarte, California, United States
Norton Cancer Institute
Louisville, Kentucky, United States
Norton Diagnostic Center - Dupont
Louisville, Kentucky, United States
Norton Women's and Children's Hospital
Louisville, Kentucky, United States
Tulane Medical Center
New Orleans, Louisiana, United States
Parexel International
Billerica, Massachusetts, United States
Start Date
December 16, 2016
Primary Completion Date
December 2, 2019
Completion Date
December 2, 2019
Last Updated
December 17, 2020
NCT05272384
NCT06395103
NCT05139017
NCT01804686
NCT07042438
NCT07443514
Lead Sponsor
Pfizer
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions